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Introduction
Glioblastoma (GBM) is the most common pri-
mary malignant brain tumor.1 Current treatment 
includes maximal safe resection, followed by radi-
otherapy with concomitant and adjuvant temozo-
lomide. However, the 2-, 3-, and 5-year overall 
survival are only 27%, 16%, and 9.8%, respec-
tively.2 One of the main factors for this poor prog-
nosis is the suboptimal local control after 
treatment. Up 77% of GBMs recur within 2 cm of 
the primary tumor,3 and 72% of cases will recur 
within the radiotherapy field.4 These treatment 
failures may largely be due to the inaccuracy 
assessment of the cancer-invasive margin; a major 
limitation of current standard anatomical mag-
netic resonance imaging (MRI) sequences.5 The 
contrast-enhanced region is the target for surgical 
resection, and radiotherapy will target a margin of 
about 2 cm around this area. However, a biopsy 
study has shown that tumor extends beyond the 
contrast-enhanced area and can even be present in 
areas with normal T2 signal.6 More reliable multi-
modal MR techniques are thus needed to identify 
the GBM-invasive margin.
Different imaging modalities had been studied to 
show the tumor infiltration. Diffusion-weighted 
imaging (DWI) can detect water diffusion and 
Multimodal MRI characteristics of the 
glioblastoma infiltration beyond contrast 
enhancement
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Abstract: Our inability to identify the invasive margin of glioblastomas hampers attempts 
to achieve local control. Diffusion tensor imaging (DTI) has been implemented clinically to 
delineate the margin of the tumor infiltration, its derived anisotropic (q) values can extend 
beyond the contrast-enhanced area and correlates closely with the tumor. However, 
its correlation with tumor infiltration shown on multivoxel proton magnetic resonance 
spectroscopy1 (MRS) and perfusion magnetic resonance imaging (MRI) should be investigated. 
In this study, we aimed to show tissue characteristics of the q-defined peritumoral invasion 
on MRS and perfusion MRI. Patients with a primary glioblastoma were included (n = 51). Four 
regions of interest were analyzed; the contrast-enhanced lesion, peritumoral abnormal q 
region, peritumoral normal q region, and contralateral normal-appearing white matter. MRS, 
including choline (Cho)/creatinine (Cr), Cho/N-acetyl-aspartate (NAA) and NAA/Cr ratios, and 
the relative cerebral blood volume (rCBV) were analyzed. Our results showed an increase in 
the Cho/NAA (p = 0.0346) and Cho/Cr (p = 0.0219) ratios in the peritumoral abnormal q region, 
suggestive of tumor invasion. The rCBV was marginally elevated (p = 0.0798). Furthermore, 
the size of the abnormal q regions was correlated with survival; patients with larger abnormal 
q regions showed better progression-free survival (median 287 versus 53 days, p = 0.001) and 
overall survival (median 464 versus 274 days, p = 0.006) than those with smaller peritumoral 
abnormal q regions of interest. These results support how the DTI q abnormal area identifies 
tumor activity beyond the contrast-enhanced area, especially correlating with MRS.
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can be used to differentiate different types of 
edema, cellularity, and degree of the malig-
nancy.7 Some studies showed a high signal of 
DWI or apparent diffusion coefficiency (ADC) 
in the GBM peritumoral area.8,9 However, it is 
still controversial to differentiate true tumor infil-
tration from the edematous brain tissue by using 
only DWI.10 Diffusion tensor imaging (DTI) has 
been evaluated as a method that is sensitive to 
detect subtle white matter changes due to glioma 
invasion, as gliomas preferentially invade along 
white matter. It has been shown that DTI can 
identify abnormalities in the peritumoral region 
beyond the contrast-enhanced area which is a 
characteristic feature of a GBM that, for instance, 
is not found in brain metastases.11 The diffusion 
tensor can be decomposed into isotropic compo-
nent (p) and anisotropic component (q),12 which 
can be used to identify whether the peritumoral 
white matter is infiltrated, displaced or disrupted 
by the GBM.13 Complex different interactions 
between infiltration, displacement, and disrup-
tion can result in different p and q patterns13,14 
Most notably, the extent of resection based on 
DTI showed that a larger volume of resection of 
the DTI q values representing tumor, prolonged 
progression-free survival and overall survival.15
In addition to the diffusion magnetic resonance 
(MR) techniques, many different neuroimaging 
modalities were also been investigated to charac-
terize the peritumoral area. Multivoxel proton 
MR spectroscopy (1H-MRS) derived a choline 
(Cho)/N-acetyl aspartate (NAA) index to repre-
sent cell turnover rate and normal neuron viability 
respectively. Abnormal H-MRS characteristics1 
can be seen in the peritumoral area in GBM which 
can be further used to differentiate GBM from the 
noninvasive meningioma.16 The perfusion MR, 
such as dynamic susceptibility contrast MRI 
(DSC-MRI) can also be useful to demonstrate the 
peritumoral infiltration due to the angiogenesis 
and hyperperfusion of a GBM.14 And the increase 
of the relative cerebral blood volume (rCBV) in 
the peritumoral nonenhanced region was found to 
be a poor clinical prognostic factor.17 Other than 
the MRI, positron emission tomography (PET) 
can also be used to indicate tumor infiltration. A 
higher uptake in the peritumoral11 C-methionine 
compared with the18 F-fluorodeoxy-glucose had 
been shown to identify tumor infiltration.18 
Moreover,11 C-methionine PET had been studied 
to prove more accurate planning of the radiation 
therapy.19
In this study, we aim to analyze the peritumoral 
tissue characteristics beyond the contrast-
enhanced lesion in the abnormal and normal 
DTI area in correlation with 1H-MRS and 
DSC-MRI. It is unknown to what extent 
1H-MRS and perfusion MRI corresponds to 
abnormal DTI-derived p and q values. Therefore, 
utilizing the DTI q abnormality map, peritu-
moral DTI-defined invasive regions of interest 
were compared with other peritumoral areas 
with normal DTI q values to provide a better 
understanding of the GBM local invasive envi-
ronment and margin delineation.
Methods
Patient population
Patients with newly diagnosed cerebral GBM 
were included consecutively from our cohort 
between 2010 and 2014. Eligible patients include 
those aged over 18-years old, with a Karnofsky 
performance score (KPS) of more than 70, and 
final pathology reported as GBM. Exclusion crite-
ria were previous cranial surgery, previous cere-
bral radiotherapy, or a known other primary 
tumor. All patients received a treatment aim of 
maximal surgical resection using neuronavigation 
(StealthStation, Medtronic, Minnesota, U.S.) and 
5-aminolevulinic acid (5-ALA) fluorescence guid-
ance. This was followed by standard radiotherapy 
with concomitant and adjuvant temozolomide 
chemotherapy.2 Preoperative MR imaging was 
performed immediately preoperatively (median 
interval 1 day, range 0–9). Written informed writ-
ten consent was obtained from every patient, and 
this project was approved by the local institutional 
review board (10/H0308/23).
MRI data acquisition
Preoperative MRI data acquisition was performed 
using a 3.0 T Siemens Magnetom MRI system 
(Siemens Healthcare, Munich, Germany) with a 
standard 12-channel head coil. Primary MR 
sequence included a volumetric 3D T1-weighted 
sequence with fat suppression acquired after the 
intravenous injection of 9 ml gadolinium (Gadovist, 
Bayer Schering Pharma, Berlin, Germany) (TR/
TE 900/2.98 ms, inversion time 900 ms; flip angle 
9°, FOV 256 × 240 mm; 176–208 slices; no slice 
gap; voxel size 1 mm3). T2-weighted fluid-attenu-
ated inversion-recovery sequence and DTI acquired 
using a single-shot echo–planar sequence (TR/TE 
JL Yan, NR Boonzaier et al.
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8300/98 ms; flip angle 90°; FOV 192 mm2; 63 
slices; no slice gap; voxel size 2 mm3) with multiple 
b values (0, 350, 650, 1000, 1300 and 1600 s/mm2) 
scanned in 12 directions. Perfusion data were 
acquired with a dynamic susceptibility weighted 
contrast-enhanced (DSC-MRI) sequence (TR/TE 
of 1500 ms/30; flip angle 90°; FOV 192 mm2; 
whole-brain coverage with a slice gap of 1.5 mm 
(19 slices); voxel size of 2 × 2 × 5 mm). 1H-MRS 
was performed using chemical-shift imaging multi-
voxel single-slice sequence (TR/TE 2000/30–
35 ms; flip angle 90°; FOV 160 mm2; voxel size 10 
× 10 × 20 mm).
Image processing
Preoperative diffusion, perfusion, 1H-MRS and post-
contrast T1-weighted images were processed and 
coregistered to T2-weighted MRI using the 
FLIRT (FMRIB’s Linear Image Registration Tool) 
function in the FMRIB Software Library (FSL) ver-
sion 5.0.0 (available at: http://fsl.fmrib.ox.ac.uk/fsl/
fslwiki/). Diffusion images were processed using 
FMRIB’s diffusion toolbox from the FSL version 
5.0.0. They were realigned to the b0 image to compen-
sate for eddy currents and motion.20 We further 
decomposed the diffusion tensor into p and q compo-
nents after eigenvalues were calculated in the DTI data 
as previously described.12 Perfusion data were pro-
cessed using NordicICE (NordicNeuroLab AS, 
Bergen, Norway) and maps of rCBV were created fol-
lowing contrast-agent leakage correction. 1H-MRS 
data were processed using the LCModel.21 The val-
ues of the Cramer–Rao lower bounds indicated by the 
program were used to evaluate the quality and reliabil-
ity of the 1H spectra, and values with standard devia-
tion (SD) > 20% were discarded.
Regions of interest and DTI pattern
The peritumoral abnormal q ROIs were calculated by 
subtracting the contrast-enhanced ROIs from the 
abnormal q areas in Matlab (MathWorks Inc., Natick, 
MA, USA). The abnormal q map was drawn manu-
ally by a neurosurgeon (JLY) using a three-dimen-
sional (3D) slicer (http://www.slicer.org/).22 Previous 
studies have shown good inter- and intrarater agree-
ment.10 Contrast-enhanced lesion ROIs were drawn 
semiautomatically by threshold selection and manual 
correction was made using a 3D slicer.
Four ROIs were compared for characterizing the 
peritumoral area outside the contrast-enhanced 
region (Figure 1):
(1) The peritumoral abnormal q ROIs;
(2) The peritumoral normal q ROIs;
(3) The contrast-enhanced ROIs (excluding 
the central necrotic part);
(4) The contralateral normal-appearing white 
matter (NAWM) ROIs.
Patients were classified into two groups according 
to the pattern of q abnormality: patients who had 
the q abnormal area larger than contrast-enhanced 
area (q > CE); and the q abnormal area equal or 
smaller than the contrast-enhanced areas (q ⩽ CE).
Statistics
Clinical characteristics including age, sex, percent-
age of the total resection of the contrast-enhanced 
tumor, use of gliadel wafer, isocitrate dehydroge-
nase-1 (IDH-1) mutation status, 6-O-methylguanine–
deoxyribonucleic acid (DNA) methyltransferase 
Figure 1. Illustration of the different ROIs.
Four regions of interests (ROIs) are indicated for 
hypothetical characteristics comparison. The red boxes 
indicate the peritumoral abnormal q ROIs in more than 
half of the MRS voxel size; the red arrow indicates the 
peritumoral ROIs with no q abnormality or less than half of 
the MRS voxel size; the orange arrow indicates the contrast-
enhanced lesion; the white arrow indicates the contralateral 
normal-appearing white matter.
MRS, magnetic resonance spectroscopy.
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(MGMT) methylation status, progression-free sur-
vival and overall survival were compared between 
the group with the q > CE and the group with the 
q ⩽ CE. Comparison of patients characteristics 
between these groups was calculated by paired t test 
for continuous data and by chi-square with Fisher’s 
exact test for small-number categorical data. Overall 
survival and progression-free survival between 
the groups were calculated by the Kaplan–Meier 
method with log-rank test. All statistics were ana-
lyzed using SPSS version 22 (IBM Inc. New York, 
U.S.). The statistical significance was defined by 
two-sided p value < 0.05.
MR data analyses
1H-MRS tissue characteristics, including total 
NAA, myo-inositol (Ins), total choline (Cho) 
including phosphocholine (PCh) and glycer-
ylphosphorylcholine (GPC), glutamate (Glu) and 
glutamine (Gln), and glutathione (GSH) were all 
calculated as a ratio to the total creatinine for each 
spectroscopy voxel. Choline/NAA ratio was also 
calculated. Due to a bigger size of MRS voxel (1 × 
1 × 2 cm), MRS voxels were included for those 
ROIs occupying more than 50% of the MRS vox-
els. This was done by two different approaches: 
visual inspection; and using a 3D voxel-wise 
approach with an in-house program in R (R 
Development Core Team, 2008; Figure 2). 
Comparing visual inspection and 3D voxel-wise 
method for MRS data retrieve, no significant dif-
ference of the data value was noted between two 
methods (Table 1). In comparison with the visual 
inspection method, using 3D voxel-wise method 
had two more sets of missing data in Cho/Cr, three 
more sets in Ins/Cr, one more set in Glu + Gln/Cr 
and one set fewer in Cho/NAA. On the other hand, 
one more missing set was found in the visual 
inspection method than the 3D voxel-wise method. 
Although not significantly different, the 3D voxel-
wise method had more objectivity for MRS data 
retrieval and eliminated potential visual bias. We 
therefore use this method in our paper.
MRS data and rCBV between different ROI 
groups were compared by using one-way analysis 
of variance test and paired t test was used to com-
pare imaging data between the peritumoral 
abnormal q ROIs and those outside abnormal q 
ROIs. This was also done using SPSS version 22 
(IBM Inc.) with statistical significance defined by 
a two-sided p value < 0.05.
Results
We included 51 patients (mean age 58.4 years, 
range 36.7–73.8) in this study. There were 12 
females and 39 males. The complete resection 
based on contrast-enhanced T1-weighted MRI 
was achieved in 76% of the patients. IDH-1 
mutation status was obtained in 32 patients, and 
3 (9%) were mutated. MGMT promoter meth-
ylation status was available in 32 patients with 16 
(50%) patients methylated. The overall survival 
was 484 days ± 312 days (median ± SD), and the 
progression-free survival was 121 ± 130 days. All 
ROIs (peritumoral abnormal q ROIs; peritumoral 
normal q ROIs; contrast-enhanced ROIs and 
contralateral NAWM ROIs) were extracted from 
all patients. Also, all spectroscopy spectra could 
be extracted for all patients.
Figure 2. 3D voxel-wise method for MRS data retrieval.
This figure illustrates the 3D voxel-wise method for MRS data retrieve. White cubes represent T2-space voxel (1 mm3), and 
the blue cubes represent regions of interest. MRS data would be included if regions of interest occupy more than half of the 
MRS voxels (red outline), otherwise it would be excluded (yellow outline).
MRS, magnetic resonance spectroscopy; 3D, three dimensional.
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1H-MRS tissue characteristics using the 3D 
voxel-wise method
Using the 3D voxel-wise approach for 1H-MRS 
data retrieve, Cho/Cr were different in all four 
ROIs [p < 0.0001, Figure 3(a)], highest in the 
contrast-enhanced ROIs, followed by peritumoral 
abnormal q ROIs, peritumoral normal q ROIs, 
and the control NAWM. Subgroup analysis 
Table 1. Comparison of different methods for MRS data retrieval.
3D voxel-wise approach Visual inspection p value
 Value Number of 
included voxels
Value Number of 
included voxels
Cho/Cr 0.486 ± 0.042 25 0.442 ± 0.021 27 0.3733
NAA/Cr 0.913 ± 0.059 25 0.946 ± 0.061 25 0.6995
Cho/NAA 0.731 ± 0.131 25 0.639 ± 0.149 24 0.6431
Ins/Cr 1.373 ± 0.121 23 1.207 ± 0.064 26 0.2164
Glu + Gln /Cr 1.842 ± 0.237 19 1.772 ± 0.138 20 0.3951
Cho, choline; Cr, creatinine; NAA, N-acetyl-aspartate; Ins, myo-inositol; Glu, glutamate; Gln, glutamine, 3D, three 
dimensional.
Figure 3. MRS and perfusion characteristics between different ROIs.
The MRS data of different chemical compounds (a–e) and rCBV (f) between different regions of interest (ROIs) are shown. 
The contrast-enhanced ROI (CE), peritumoral abnormal q ROIs and the peritumoral ROIs without q abnormality, and the 
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showed higher Cho/Cr in the peritumoral q abnor-
mality area than the peritumoral normal q area 
(p = 0.0219). Total NAA/Cr showed an increase 
in the contrast-enhanced ROIs [p < 0.0001, Figure 
3(b)], but no significant difference between peritu-
moral q abnormal ROIs and normal q ROIs (p = 
0.3532). Significant elevation of Cho/NAA ratio 
was noted in the contrast-enhanced ROIs [p < 
0.0001, Figure 3(c)]. In peritumoral q abnormal 
ROIs, an increase in the Cho/NAA ratio was seen 
compared with the normal q ROIs (p = 0.0346) 
and control NAWM (p = 0.0021). The Glu/Cr 
was found to be higher over the contrast-enhanced 
ROIs and peritumoral q abnormal ROIs than the 
control NAWM [p < 0.0001 and p = 0.0158, 
respectively; Figure 3(d)]. Glu/Cr of the abnormal 
q ROIs was not statistically significantly different 
from the normal q ROIs (p = 0.6981) and control 
(p = 0.0682). However, there was a significant 
decrease in Ins/Cr in the peritumoral abnormal q 
ROIs, compared with the contrast-enhanced ROIs 
and control NAWM [p < 0.0001 and p = 0.0011, 
respectively; Figure 3(e)].
rCBVs were higher in contrast-enhanced ROIs 
and all peritumoral areas than the control NAWM 
(p < 0.0001). Subgroup analysis showed mar-
ginal increase of rCBV in peritumoral q abnormal 
ROIs compared with the peritumoral normal q 
ROIs [p = 0.0798, Figure 3(f)].
Clinical outcome of different q abnormality 
patterns
A total of 28 out of 51 patients had the q abnor-
mality area greater than the contrast-enhanced 
area for at least ½ of the MRS voxel, while 23 out 
of 51 patients had q abnormality area equally or 
smaller than the enhanced area. The overall sur-
vival was significantly longer than those with a 
larger q abnormality area [median: 464 versus 
274 days, p = 0.0055; Figure 4(a)]. And the pro-
gression-free survival is also longer in this larger q 
abnormal ROIs group (median: 287 versus 
53 days, p = 0.0013). A bias from other patients 
characteristics is unlikely as there were no statisti-
cal difference in age, gender, total resection of the 
contrast-enhanced lesion, use of gliadel wafer, 
MGMT methylation status and IDH-1 mutation 
status between two groups of patients (Table 2).
Discussion
In this study, the abnormal peritumoral q area 
indicative of tumor infiltration beyond the con-
trast-enhanced area corresponded to tumor infil-
tration on 1H-MRS with an increase in Cho/NAA 
and Cho/Cr. Furthermore, a higher rCBV was also 
suggested. This provides support for the delinea-
tion of the tumor infiltration margin with DTI. 
The is of particular relevance, as abnormal DTI q 
ROIs demonstrated an impact on survival. It is 
clear that GBM cells can extend beyond contrast-
enhanced lesions, as previously, researchers 
showed tumor infiltration of the peritumoral region 
outside the contrast enhancement on biopsy stud-
ies in up to one third of patients.23 However, con-
ventional structural MRI sequences fail to detect 
this invasive margin. Many studies have attempted 
to use multimodal MRI of the peritumoral areas to 
differentiate GBM from less invasive metastatic 
brain tumors or benign brain tumors.14 DTI is 
promising for showing peritumoral infiltration. 
Min and colleagues showed a significant higher 
Figure 4. Survival difference between different q abnormality patterns.
Figure 4 shows the different overall survival between different q abnormality patterns. For patients with q abnormal ROIs 
larger than contrast-enhanced area, log-rank test showed a longer overall survival than patients with smaller q abnormal 
ROIs [4(a), p = 0.0055]. Furthermore, progression-free survival was also longer in the larger q abnormal ROIs group [4(b),  
p = 0.0013].
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regression coefficiency of radial diffusivity to axial 
diffusivity and a lower fractional anisotropy (FA);24 
and Wang and colleagues also showed a decrease 
in the q component of DTI in the peritumoral 
area. Furthermore, our previous biopsy studies 
also showed that abnormal DTI, especially in the q 
area, represents tumor-cell infiltration.13 Therefore, 
DTI can better define the GBM-invasive margin.14 
Although other non-q DTI is not demonstrated by 
all. Tsougos and colleagues showed inconsistent 
results of DTI in the peritumoral areas, with no 
difference in the ADC or FA between the peritu-
moral area and control area.25
It this study, we showed that tumor infiltration of 
the abnormal q area corresponds with tumor infil-
tration detection on 1H-MRS. Our results showed 
an increase in cell turnover rate (increase in Cho/
Cr) in the peritumoral region in the abnormal q 
ROIs, which was also significantly higher com-
pared with the peritumoral normal q ROIs. 
Although NAA/Cr showed no difference between 
abnormal q and normal q ROIs, NAA/Cr in all 
peritumoral ROIs were lower than the contralat-
eral control which is compatible with other studies. 
Tsougos and colleagues had shown an increase in 
Cho/Cr, rCBV and a decrease in NAA/Cr were 
found in the peritumoral areas of GBM compared 
with metastatic tumors.25 Other studies showed an 
increase in Cho/Cr, Cr/NAA, and Ins/Cr.16 In our 
results, an increase of Glu/Cr in both the contrast-
enhanced ROIs and in the peritumoral abnormal q 
ROIs compared with the contralateral control 
NAWM indicates tumor activity and the Glu is 
known to play an important role in tumor inva-
sion.26 Therefore, this showed an increase in inva-
sive potential from these peritumoral q abnormal 
ROIs. Next, our results showed a decreased level 
of Ins/Cr in the peritumoral ROIs especially in the 
q normal area. Ins is known as a cerebral osmolyte 
and astrocyte marker that can be seen in various 
intracranial pathology.27 Therefore, a decrease in 
Ins/Cr may be due to peritumoral brain edema.26 
Besides, compared with the contralateral control, 
our results did not show a decrease of Ins/Cr in the 
contrast-enhanced area. The increase of Ins/Cr 
can be due to astrocytosis or myelin destruction. 
But the change of the Ins/Cr level is variable: 
Castillo and colleagues showed an increase of Ins/
Cr in low-grade glioma and a decrease in GBM.28 
This result may be due to a possible elevation of 
the Ins/Cr in the contralateral NAWM that 
Kellenberg and colleagues had described, where 
possible tumor infiltration in the contralateral cer-
ebral hemisphere of the untreated GBM patients 
was associated with an increase of Ins.
Our DSC-MRI showed marginal higher rCBV in 
the peritumoral abnormal q ROIs than in the nor-
mal q ROIs (p = 0.0798). This is supported by 
Table 2. Clinical characteristics in patients with a different q abnormality pattern.
q ⩽ T1C q > T1C p value
n 23 28  
Age, years (mean ± SD) 60.09 ± 2.312 57.40 ± 2.061 0.490
Sex (M/F, %) 50/50 84/17 0.061
Complete resection CE (% of patients) 75 75 n.s.
Gliadel use (%) 56.25 70.8 0.486
IDH-1 mutation (n) 1 3 0.609
MGMT methylation (n) 9 11 n.s.
Progression-free survival (days) 53 287 0.001
Overall survival (days) 274 464 0.006
Patients with q abnormality areas smaller or equal to contrast-enhanced areas (q ⩽ T1C) are compared with patients with 
q abnormality areas larger than the contrast-enhanced areas for more than half of MRS voxel size (q > T1C).
CE, contrast enhanced; IDH-1, isocitrate dehydrogenase-1; MGMT, O6-methylguanine-deoxyribonucleic acid 
methyltransferase; MRS, magnetic resonance spectroscopy; n.s., not significant; SD, standard deviation; T1C, contrast-
enhanced areas.
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previous studies showing increased peritumoral 
rCBV in GBM (REF). An increase of rCBV results 
in increased tumor density followed by hypoxia then 
angiogenesis, which is correlated with cellular pro-
liferation in high-grade glioma.29 Other groups have 
shown that the site of increased rCBV may poten-
tially also predict sites of tumor progression.30
Lastly, our study has shown that different pat-
terns of abnormal q ROIs impact clinical out-
come. We have shown that there is a better 
overall survival and progression-free survival in 
those with larger abnormal q ROIs than contrast-
enhanced areas. This was independent of age, 
resection type, IDH-1 mutation status and 
MGMT methylation status between two groups. 
And all patients in our cohort were KPS > 70 
and received the same treatment protocol includ-
ing 5-ALA-guided surgical resection followed by 
postoperative temozolomide chemoradiotherapy 
and adjuvant temozolomide therapy. Our previ-
ous studies showed DTI abnormality patterns 
can be classified into localized, minimal and dif-
fused types and are associated with prognosis.31 
The classification was based on the relationship 
of p and q abnormal areas but not with the con-
trast-enhanced area. Different invasion patterns 
thus might result in different prognoses. 
Furthermore, the abnormal q ROIs representing 
tumor-cell infiltration showed a higher Cho/Cr 
level, which represents a higher cell turnover 
rate. Although a better survival in patients with 
more abnormal q indicating tumor might seem 
contra-intuitive, higher Cho in the abnormal q 
region is hypothesized to facilitate increased 
chemoradiosensitivity, which may explain the 
better survival in these patients. However, a 
guided biopsy study is needed in future to corre-
late the MRS, biologic characteristics, and this 
clinical presentation. And our better survival in 
relation to a higher Cho is, however, not widely 
supported, as a small study with 14 patients 
showed that lower baseline NAA/Cr and higher 
Cho/Cr in the peritumoral nonenhanced region 
were associated with poor outcome.32
A common limitation in 1H-MRS studies is a vis-
ual selection of the MRS voxels. Most studies use 
visual inspection by an experienced expert to select 
the MRS voxel from the overlaying ROIs. However, 
as the MRS voxel is usually larger than other MRI 
sequences, and the shape of the GBM often grows 
irregularly. We used two different methods to select 
ROIs in MRS voxel. Next, to visually inspect, we 
performed a 3D voxel-wise approach with which 
the MRS data were automatically retrieved accord-
ing to the different ROIs. This may minimize pos-
sible error in visual inspection. By using this 
method, we found more missing data that showed 
this automatic selection had a higher standard on 
the MRS voxel quality control. Although there was 
no statistical difference between the metabolite val-
ues of the two methods, this still provides a more 
objective method for MRS data retrieval and elimi-
nates possible visual bias.
Another limitation of our study is that 5-ALA is 
used during surgery. This might influence the 
survival of the patients as it can potentially influ-
ence the extent of the resection of the peritumoral 
nonenhanced area.33 As 5-ALA is used in all 
patients, a potential bias in survival is expected to 
equally influence all patients.
In conclusion, the peritumoral invasive margin can 
be identified by using DTI q. In ROIs of peritu-
moral abnormal q area, there was higher Cho/NAA 
and Cho/Cr which indicates tumor activity. Also, 
rCBV was marginally elevated in line with tumor 
infiltration. In addition, different patterns of the 
peritumoral abnormal q may have clinical implica-
tion as a larger abnormal q than contrast-enhanced 
lesion showed a better progression-free survival and 
overall survival. Our results demonstrate the rele-
vance of the peritumoral area and indicate its poten-
tial target for therapeutic interventional studies.
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